Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ).
Clarity Pharmaceuticals Ltd. has announced that Vanguard Group, a significant shareholder, has ceased to be a substantial holder in the company as of May 30, 2025. This change in Vanguard Group’s holding reduces its voting power to 4.840%, potentially impacting Clarity Pharmaceuticals’ shareholder dynamics and market perception.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Average Trading Volume: 2,894,035
Technical Sentiment Signal: Sell
Current Market Cap: A$609M
For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.